Table 1 Clinical and disease characteristics at baseline and 6 months (for MADRS score).
Variable | N | Percentage | Mean (SD) | Standard Deviation | Range (Min-Max) |
|---|---|---|---|---|---|
Age | 60 | - | 53.3 | 15.01 | 18–77 |
Number MDE (lifetime) | 60 | - | 4.8 | 3.99 | 0–20 |
Disease duration (years) | 60 | - | 17.5 | 15.15 | 0–60 |
MDE duration (months) | 60 | - | 42.35 | 47.61 | 1–200 |
Baseline MADRS score | 60 | - | 26.82 | 6.09 | 16–43 |
MADRS score 6-month follow-up | 60 | - | 15.2 | 10.66 | 0–40 |
MADRS score raw change between baseline and 6-month follow-up | 60 | - | −11.62 | 10.24 | −35–7 |
State anxiety score (baseline) | 60 | - | 57.7 | 12.52 | 28–78 |
Trait anxiety score (baseline) | 60 | - | 58.33 | 13.31 | 22–79 |
Anhedonia score (baseline) | 60 | - | 5.43 | 3.99 | 0–14 |
Medication load index | 60 | - | 3.37 | 1.28 | 1–7 |
Sex [ref = Female] | 60 | 41 (68.33%) | - | - | - |
Mood Disorder [ref = Bipolar] | 60 | 33 (55%) | - | - | - |
Thase and Rush stage | 54 | - | - | - | Stage 0: 1 (1.9%); Stage 1: 7 (13.0%); Stage 2: 20 (37.0%); Stage 3: 21 (38.9%); Stage 4: 5 (9.3%) |
